3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Advanced Solid Tumors
1
Interventions
pembrolizumab
95
Specimen Handling
79
Magnetic Resonance Spectroscopy
70
Carboplatin
59
Cisplatin
56
Biopsy
56
Nivolumab
51
Radiotherapy
47
Cyclophosphamide
44
Paclitaxel
43
Radiation
36
durvalumab
33
Gemcitabine
31
olaparib
30
Dexamethasone
30
Etoposide
29
Doxorubicin
28
atezolizumab
26
Taxes
25
Rituximab
25
Docetaxel
25
Ipilimumab
24
Bevacizumab
24
Vincristine
23
Lenalidomide
23
Pemetrexed
22
Cytarabine
22
X-Rays
21
Radiotherapy, Intensity-Modulated
21
Prednisone
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Antiemetics
×
90 days
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts